Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$1.32 USD

1.32
220,595

+0.01 (0.76%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $1.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

by Zacks Equity Research

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -8.20% and 169.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.

Spero Therapeutics (SPRO) Catches Eye: Stock Jumps 7%

by Zacks Equity Research

Spero Therapeutics (SPRO) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 27.35% and -41.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics, Inc. (SPRO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. (SPRO).

Spero Therapeutics Inc (SPRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics Inc (SPRO) delivered earnings and revenue surprises of 9.63% and -49.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -21.10% and 2.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iterum Down as Sulopenem Antibiotic Fails in Phase III Study

by Zacks Equity Research

Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

by Zacks Equity Research

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -18.75% and 128.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 62.34% and 517.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Gets Fast Track Designation for SPR994, Shares Improve

by Zacks Equity Research

Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.

Will Spero Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Spero Therapeutics.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 6.25% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?